Show simple item record

2021-12-20Zeitschriftenartikel
Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
dc.contributor.authorLassaunière, Ria
dc.contributor.authorPolacel, Charlotta
dc.contributor.authorGram, Gregers J.
dc.contributor.authorFrische, Anders
dc.contributor.authorTingstedt, Jeanette Linnea
dc.contributor.authorKrüger, Maren
dc.contributor.authorDorner, Brigitte G.
dc.contributor.authorCook, Anthony
dc.contributor.authorBrown, Renita
dc.contributor.authorOrekov, Tatyana
dc.contributor.authorPutmon-Taylor, Tammy
dc.contributor.authorCampbell, Tracey-Ann
dc.contributor.authorGreenhouse, Jack
dc.contributor.authorPessaint, Laurent
dc.contributor.authorAndersen, Hanne
dc.contributor.authorLewis, Mark G.
dc.contributor.authorFomsgaard, Anders
dc.date.accessioned2024-08-14T12:46:24Z
dc.date.available2024-08-14T12:46:24Z
dc.date.issued2021-12-20none
dc.identifier.other10.1038/s41541-021-00419-z
dc.identifier.urihttp://edoc.rki.de/176904/11922
dc.description.abstractNew generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying platform optimization strategies, we tested the pre-clinical immunogenicity and protective effect of a candidate DNA plasmid vaccine specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The DNA vaccine induced spike-specific binding IgG and neutralizing antibodies in mice, rabbits, and rhesus macaques together with robust Th1 dominant cellular responses in small animals. Intradermal and intramuscular needle-free administration of the DNA vaccine yielded comparable immune responses. In a vaccination-challenge study of rhesus macaques, the vaccine demonstrated protection from viral replication in the lungs following intranasal and intratracheal inoculation with SARS-CoV-2. In conclusion, the candidate plasmid DNA vaccine encoding the SARS-CoV-2 spike protein is immunogenic in different models and confers protection against lung infection in nonhuman primates. Further evaluation of this DNA vaccine candidate in clinical trials is warranted.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titlePreclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2none
dc.typearticle
dc.identifier.urnurn:nbn:de:0257-176904/11922-8
dc.type.versionpublishedVersionnone
local.edoc.container-titlenpj Vaccinesnone
local.edoc.container-issn2059-0105none
local.edoc.pages13none
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.nature.com/npjvaccines/none
local.edoc.container-publisher-nameSpringer Naturenone
local.edoc.container-volume6none
local.edoc.container-issue156none
local.edoc.container-reportyear2021none
dc.description.versionPeer Reviewednone

Show simple item record